PHASE GENOMICS

CytoTerra® Platform

Access New Insights in Precision Oncology

Comprehensive Cytogenetics of Fresh, Frozen, and FFPE Tissue with a Single Assay

- Surpass the breadth and depth of karyotyping, FISH, and CMA with a single, NGS-based assay
- Genome-wide cytogenetic information from a wide variety of sample types, including blood and FFPE tissue
- Scalable, fast, and cost-effective—no cell culture or dedicated instrumentation required
- Integrated sample-to-report product, no advanced NGS experience needed



Genome-wide view of large-scale changes in chromosome structure



High-resolution mapping of genomic breakpoints



Chromosome-scale mapping of deletions, amplifications, and allele frequency

Homologous Recombination Deficiency (HRD) Assessment



Comprehensively capture genomic scarring

Cancers that demonstrate phenotypic homologous recombination deficiency (HRD) are candidates for treatment with drugs that exploit synthetic lethality. The CytoTerra® Platform captures the range of genomic scars that result from HRD, including those that are difficult to detect with whole genome sequencing.

FFPE Applications

- The CytoTerra® Platform enables high-resolution cytogenetic analysis of solid tumors—samples that are unsuitable for traditional cytogenetics
- Identify balanced and unbalanced chromosomal aberrations including copy-neutral loss of heterozygosity (cnLOH); all with a fraction of sequencing costs associated with whole genome sequencing
- Identify novel and known druggable gene fusions and other indications for precision oncology therapies
- Recover genome-wide insights from as little as 2 x 5 µm FFPE curls



High complexity breast tumor sample



NPM1-ALK1 fusion; **Crizotinib**



RB1 disruption; **Volasertib**



Novel *NTRK2* fusion; **Entrectinib**



Intermediate complexity breast tumor sample



MYC amplification; **Omomyc**

BRCA2 deletion; **Olaparib**

Learn more

PHASE GENOMICS

info@phasegenomics.com
www.phasegenomics.com

Phone: 1-833-742-7436
Twitter: @PhaseGenomics

Unless otherwise stated, data on file.
For Research Use Only. Not for use in diagnostic procedures.
CYTOTERRA is a trademark of Phase Genomics, Inc. All other product names and trademarks are the property of their respective owners.